MCID: PRK045
MIFTS: 44

Parkinson Disease 5 malady

Categories: Genetic diseases, Neuronal diseases, Mental diseases, Rare diseases, Metabolic diseases

Aliases & Classifications for Parkinson Disease 5

About this section

Aliases & Descriptions for Parkinson Disease 5:

Name: Parkinson Disease 5 52 70 68
Parkinson Disease 5, Susceptibility to 27 12
Parkinson Disease 5, Autosomal Dominant, Susceptibility to 70
 
Parkinson Disease 5, Autosomal Dominant 68
Parkinson Disease Autosomal Dominant 5 70
Park5 70

Classifications:



External Ids:

OMIM52 613643
MedGen37 C3150899
MeSH39 D010300

Summaries for Parkinson Disease 5

About this section
UniProtKB/Swiss-Prot:70 Parkinson disease 5: A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (resting tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia.

MalaCards based summary: Parkinson Disease 5, also known as parkinson disease 5, susceptibility to, is related to parkinson disease, late-onset and uchl1-related parkinson disease susceptibility. An important gene associated with Parkinson Disease 5 is UCHL1 (Ubiquitin C-Terminal Hydrolase L1), and among its related pathways are Paroxetine Pathway, Pharmacokinetics and SIDS Susceptibility Pathways. Affiliated tissues include brain, testes and cortex, and related mouse phenotypes are behavior/neurological and cardiovascular system.

Description from OMIM:52 613643

Related Diseases for Parkinson Disease 5

About this section

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 7, Autosomal Recessive Early-Onset Parkinson Disease 6, Early Onset
Parkinson Disease 19, Juvenile-Onset Parkinson Disease 10
Parkinson Disease 16 Parkinson Disease 13
Parkinson Disease 11 Parkinson Disease 21
Parkinson Disease 18 parkinson disease 5
Parkinson Disease 4 Parkinson Disease 1
Parkinson Disease, Juvenile, Type 2 Parkinson Disease 8
Parkinson Disease 17 Parkinson Disease 20, Early-Onset
Parkinson Disease 15, Autosomal Recessive Parkinson Disease 14, Autosomal Recessive
Parkinson Disease 12 Lrrk2-Related Parkinson Disease
Parkinson Disease Type 3 Parkinson Disease Type 9
Dnajc6-Related Parkinson Disease Eif4g1-Related Parkinson Disease
Gigyf2-Related Parkinson Disease Pla2g6-Related Parkinson Disease
Synj1-Related Parkinson Disease Fbxo7-Related Parkinson Disease
Htra2-Related Parkinson Disease Park7-Related Parkinson Disease
Snca-Related Parkinson Disease Vps35-Related Parkinson Disease
Hereditary Late-Onset Parkinson Disease Parkinson Disease 22
Parkinson Disease 23, Autosomal Recessive, Early Onset

Diseases related to Parkinson Disease 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
idRelated DiseaseScoreTop Affiliating Genes
1parkinson disease, late-onset29.1COMT, HTR2A, MAPT, SLC6A4, UCHL1
2uchl1-related parkinson disease susceptibility10.9
3brain meningioma10.1COMT, UCHL1
4hemorrhagic cystitis10.1COMT, SLC6A4
5anosognosia10.1COMT, SLC6A4
6tongue disease10.1COMT, SLC6A4
7meckel's diverticulum10.1COMT, SLC6A4
8splenic disease10.1HTR2A, SLC6A4
9conjunctival degeneration10.1HTR2A, SLC6A4
10idiopathic neonatal atrial flutter10.1HTR2A, SLC6A4
11chagas disease10.0HTR2A, SLC6A4
12phlegmonous dacryocystitis10.0COMT, SLC6A4
13lipedematous scalp10.0COMT, HTR2A
14lymphosarcoma10.0COMT, SLC6A4
15central sleep apnea10.0HTR2A, SLC6A4
16mixed malaria10.0HTR2A, SLC6A4
17dysthymic disorder10.0HTR2A, SLC6A4
18pervasive developmental disorder9.9COMT, SLC6A4
19laryngeal adductor paralysis9.9HTR2A, SLC6A4
20diabetic encephalopathy9.9HTR2A, SLC6A4
21alcoholic liver cirrhosis9.9HTR2A, SLC6A4
22phka2-related phosphorylase kinase deficiency9.9MAPT, UCHL1
23periampullary adenoma9.9HTR2A, SLC6A4
24ulcerative colitis9.8COMT, SLC6A4, UCHL1
25autoimmune-related retinopathy and optic neuropathy9.7HTR2A, SLC6A4
26sudden infant death syndrome9.7HTR2A, SLC6A4
27cardiomyopathy, dilated, 1u9.7MAPT, UCHL1
28vogt-koyanagi-harada disease9.7COMT, HTR2A, SLC6A4
29obsessive-compulsive personality disorder9.6COMT, HTR2A, SLC6A4
30adrenal gland pheochromocytoma9.6COMT, MAPT
31maternal uniparental disomy of chromosome 139.6COMT, HTR2A, SLC6A4
32hypoglycemic coma9.6COMT, HTR2A, SLC6A4
33phaeohyphomycosis9.6COMT, HTR2A, SLC6A4
34chronic cervicitis9.6COMT, HTR2A, SLC6A4
35vulvar disease9.6COMT, HTR2A, SLC6A4
36albinism, oculocutaneous, type v9.6HTR2A, SLC6A4
37pyoderma gangrenosum9.6COMT, HTR2A, SLC6A4
38enthesopathy9.6COMT, HTR2A, SLC6A4
39vernal conjunctivitis9.6COMT, HTR2A, SLC6A4
40parkinsonism-dystonia, infantile9.6COMT, HTR2A, SLC6A4
41fechtner syndrome9.6COMT, HTR2A, SLC6A4
42purpura9.6COMT, HTR2A, SLC6A4
43acatalasemia9.6COMT, HTR2A, SLC6A4
44aicardi-goutieres syndrome 29.6COMT, HTR2A, SLC6A4
45sexual disorder9.6COMT, HTR2A, SLC6A4
46narcolepsy 29.6COMT, HTR2A, SLC6A4
47craniosynostosis, adelaide type9.6COMT, HTR2A, SLC6A4
48avoidant personality disorder8.9COMT, HTR2A, MAPT, SLC6A4
49hypersensitivity syndrome, carbamazepine-induced8.9MAPT, SLC6A4, UCHL1
50neurodegeneration with optic atrophy, childhood onset8.6COMT, HTR2A, MAPT, SLC6A4, UCHL1

Graphical network of the top 20 diseases related to Parkinson Disease 5:



Diseases related to parkinson disease 5

Symptoms & Phenotypes for Parkinson Disease 5

About this section


Clinical features from OMIM:

613643

MGI Mouse Phenotypes related to Parkinson Disease 5 according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053868.3COMT, HTR2A, MAPT, SLC6A4, UCHL1
2MP:00053858.2COMT, MAPT, SLC6A4, UCHL1

Drugs & Therapeutics for Parkinson Disease 5

About this section

Drugs for Parkinson Disease 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 274)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Rivastigmineapproved, investigationalPhase 4, Phase 383123441-03-277991
Synonyms:
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
123441-03-2
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate
AB1004572
AC1L2U92
BIDD:GT0316
C11766
CHEMBL636
CID77991
Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester
Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
D03822
DB00989
ENA 713 free base
 
Ena 713 Free Base
Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Exelon
Exelon Patch
HMS2089H18
I06-2037
LS-172571
MolPort-003-666-662
NCGC00167531-01
Rivastigmine (JAN/USAN/INN)
Rivastigmine Hydrogen Tartrate
Rivastigmine [USAN:INN]
Rivastigmine hydrogen tartrate
SDZ 212-713
UNII-PKI06M3IW0
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
rivastigmine
2
DopamineapprovedPhase 4, Phase 3, Phase 2, Phase 1375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
3
LevodopaapprovedPhase 4, Phase 3, Phase 2, Phase 138859-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
4
DonepezilapprovedPhase 4, Phase 3, Phase 2, Phase 1280120014-06-43152
Synonyms:
( inverted exclamation markA)-E 2020
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
120014-06-4
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC-6969
AC1L1FAE
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
 
Donepezil
Donepezil (INN)
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum5_001662
Spectrum_001664
TL8000531
UNII-8SSC91326P
5
CarbidopaapprovedPhase 4, Phase 3, Phase 2, Phase 117728860-95-934359, 38101
Synonyms:
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(S)-(-)-carbidopa
(S)-(-)-carbidopa hydrate
(S)-(−)-carbidopa
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-carbidopa hydrate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C-DOPA
C126_SIGMA
C1335_SIGMA
CCRIS 5093
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
Carbidopa (anhydrous)
Carbidopa Anhydrous
Carbidopa Monohydrate
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa, (S)-Isomer
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
 
Carbidopum
Carbidopum [INN-Latin]
DB00190
EINECS 249-271-9
EU-0100382
HMS2089B12
Hadrazino-alpha-methyldopa
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
L-α-methyldopahydrazine
LS-77199
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
Methyldopahydrazine
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S(-)-CARBIDOPA
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
carbidopa
carbidopum monohydricum
6
Entacaponeapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 151130929-57-65281081
Synonyms:
(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
(E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide
(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
(e)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
116314-67-1
130929-57-6
2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
AC-393
AC1NQY02
BIDD:GT0026
C071192
C07943
C14H15N3O5
CHEBI:4798
CHEMBL953
CID5281081
COM-998
Comtan
Comtan (TN)
Comtess
D00781
 
DB00494
ENTACAPONE
Entacapona
Entacapona [INN-Spanish]
Entacapone
Entacapone (JAN/USAN/INN)
Entacapone [USAN:INN]
Entacapone [Usan:Inn]
Entacaponum
Entacaponum [INN-Latin]
HMS2089O16
KB475572
LS-123327
LS-172316
MolPort-003-847-054
N,N-Diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
NCGC00164555-01
Novartis brand of entacapone
OR 611
OR-611
Orion brand of entacapone
UNII-4975G9NM6T
entacapone
7
NorepinephrineapprovedPhase 4, Phase 268351-41-2439260
Synonyms:
(-)-(R)-Norepinephrine
(-)-Arterenol
(-)-Arterenol free base
(-)-NORADRENALINE
(-)-Noradrenaline
(-)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(R)-(-)-Norepinephrine
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
AC1L96ZT
ALBB-006229
Adrenor
Aktamin
Arterenol
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
DivK1c_000230
EINECS 200-096-6
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-3,4-Dihydroxyphenylethanolamine
L-3,4-dihydroxyphenylethanolamine
L-Arterenol
L-Noradrenaline
L-Norepinephrine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-noradrenaline
LS-42676
LT03330026
 
LT4
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Nor-Epirenan
Nor-adrenaline
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
Noradrenaline
Noradrenaline (JP15)
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
Norepinefrina
Norepinephrine
Norepinephrine (INN)
Norepinephrine Noradrenalin
Norepinephrine [INN:JAN]
Norepinephrine l-Tartrate (1:1)
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
PDSP1_001111
PDSP2_001095
SGCUT00123
SPBio_001048
SPECTRUM1500436
STK503776
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
Spectrum_001009
Sympathin E
UNII-X4W3ENH1CV
bmse000404
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
noradrenaline
norepinefrina
norepinephrine
norepinephrinum
to_000024
8
CabergolineapprovedPhase 44681409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
9
Pramipexoleapproved, investigationalPhase 4, Phase 3, Phase 2139104632-26-059868, 119570
Synonyms:
(-)-Pramipexole
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
104632-26-0
111GE001
2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
2-amino-6-propylaminotetrahydrobenzothiazole
AC1L3P1T
BIDD:GT0250
C10H17N3S
CHEBI:8356
CHEMBL301265
CID119570
CPD000449298
D05575
DivK1c_006916
Furfuryl Acetate
HMS2051A21
HMS2090C15
KBio1_001860
KBio2_002340
KBio2_004908
 
KBio2_007476
KBioSS_002343
LS-40722
MLS000758250
MLS001423952
Mirapex
MolPort-003-849-957
NCGC00167441-01
Pramipexol
Pramipexol [Spanish]
Pramipexole
Pramipexole (USAN/INN)
Pramipexole 2HCl Monohydrate
Pramipexole [USAN:INN]
Pramipexole hydrochloride
Pramipexolum
Pramipexolum [Latin]
SAM001247006
SBB070477
SMR000449298
SND-919
SUD919CL2Y
SpecPlus_000820
Spectrum5_001453
Spectrum_001838
U-98528E
pramipexole
10
Apomorphineapproved, investigationalPhase 4, Phase 3, Phase 23741372-20-7, 58-00-46005
Synonyms:
(-)-10,11-Dihydroxyaporphine
(6AR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(6aR)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo(de,g)chinolin-10,11-diol
(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(R)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol
(R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol
(R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(−)-10,11-dihydroxyaporphine
314-19-2 (hydrochloride anhydrous)
41372-20-7 (hydrochloride hemihydrate)
4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, (R)- (9CI)
4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, HCl, (R)-, hemihydrate
58-00-4
6a-beta-Aporphine-10,11-diol
6a-beta-Aporphine-10,11-diol, hydrochloride, hemihydrate
6abeta-Aporphine-10,11-diol
AC1L1LLC
Apokyn
Apomorfin
Apomorphin
Apomorphine (BAN)
Apomorphine HCl hydrate
Apomorphine Hydrochloride Hemihydrate
Apomorphine hydrochloride
Apomorphine hydrochloride hemihydrate
Apomorphinium Chloride Hemihydrate
Apomorphinium chloride hemihydrate
Apormorphine
BPBio1_000092
BPBio1_001179
BRD-K76022557-001-01-3
BSPBio_000082
Biomol-NT_000019
C17H17NO2
 
CE0800000
CHEBI:48538
CID6005
D07460
DB00714
EINECS 200-360-0
HMS2089C10
HSDB 3289
IV Apomorphine
Ixense
L-Apomorphine
LS-21474
NCGC00025349-01
NCGC00025349-02
NIOSH/CE0800000
PDSP1_000780
PDSP2_001488
Prestwick0_000101
Prestwick1_000101
Prestwick2_000101
Prestwick3_000101
R-(-)-Apomorphine
R-(−)-apomorphine
SMP1_000027
SPBio_002021
STOCK1N-03149
Tocris-2073
UNII-N21FAR7B4S
Uprima
Uprima (TN)
VR-040
VR-400
VR004
apomorphine
nchembio.307-comp3
nchembio873-comp6
11
Modafinilapproved, investigationalPhase 4, Phase 219568693-11-84236
Synonyms:
Dea No. 1680
Modafinil
Modafinil [USAN:INN]
Modafinil [Usan:Inn]
Modafinilo
Modafinilo [Spanish]
 
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Provigil
Sparlon
modafinil
12
RasagilineapprovedPhase 4, Phase 354136236-51-63052776
Synonyms:
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
(1R)-N-Propargylindan-1-amine
(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
(R)-Indan-1-yl-prop-2-ynyl-amine
(R)-N-2-Propynyl-1-indanamine
136236-51-6
1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
AC-723
AC1MHJZT
Azilect
Azilect (TN)
CHEBI:45357
 
CHEMBL887
CID3052776
D08469
DB01367
LS-186771
LS-187776
MolPort-003-850-132
NCGC00168774-01
RAS
Rasagiline (INN)
Rasagiline [INN]
UNII-003N66TS6T
ZINC19875504
rasagiline
13
Armodafinilapproved, investigationalPhase 4, Phase 2195112111-43-0
Synonyms:
 
(–)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide
R-modafinil
14
Ropiniroleapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 17391374-20-8, 91374-21-95095, 497540
Synonyms:
1,3-Dihydro-4-(2-(dipropylamino)ethyl)-2H-indol-2-one monohydrochloride
2(H)-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, monohydrochloride
2H-Indol-2-one, 1,3-dihydro-4-(2-(dipropylamino)ethyl)-, monohydrochloride
2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, hydrochloride (1:1)
4-(2-(Dipropylamino)ethyl)-2-indolinone monohydrochloride
4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one
4-[2-(Dipropylamino)ethyl]indoline-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one hydrochloride
91374-20-8
91374-20-8 (hydrochloride)
91374-21-9
91374-21-9 (Parent)
AB1004799
AC-735
AC1L1JLL
AC1L2ABS
AC1Q3EQJ
AR-1L3132
Adartrel
BIDD:GT0826
BRD-K15933101-003-01-2
C07564
CHEBI:8888
CHEMBL1200411
CHEMBL589
CID5095
CID68727
D00784
D08489
DB00268
EU-0101101
HMS2093K04
I06-0692
I06-0693
JZP-7
L000520
LS-83828
LS-83890
Lopac-R-4152
Lopac0_001101
 
MolPort-003-666-598
MolPort-003-987-439
NCGC00015893-01
NCGC00015893-04
NCGC00094373-01
NCGC00096064-01
NCGC00096064-02
NVD-434
R 4152
ReQuip
ReQuip CR
ReQuip LP
ReQuip XL
ReQuip XR
Repreve
Requip (TN)
Ropinirol
Ropinirol [INN-Spanish]
Ropinirole
Ropinirole (INN)
Ropinirole HCl
Ropinirole [INN:BAN]
Ropinirole hydrochloride
Ropinirole hydrochloride (JAN/USAN)
Ropinirole hydrochloride [USAN]
Ropinirolum
Ropinirolum [INN-Latin]
Ropitor
Ropitor (TN)
SK&F 101468
SK&F 101468-A
SK&F-101,468
SK&F-101468-A
SK&F-101468A
SKF 101468
SKF 101468-A
SPECTRUM1505178
ST51051236
TL8005858
TL8005859
UNII-030PYR8953
UNII-D7ZD41RZI9
ropinirol
15
TrimethobenzamideapprovedPhase 46138-56-75577
Synonyms:
N-[[4-(2-Dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamide
Trimethobenzamidum
 
Trimethobenzamidum [INN-Latin]
Trimetobenzamida
Trimetobenzamida [INN-Spanish]
16
Methylphenidateapproved, investigationalPhase 4373113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
 
Methyl phenidyl acetate
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
17
AcetylcholineapprovedPhase 4, Phase 3, Phase 177651-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
18
Selegilineapproved, investigational, vet_approvedPhase 42714611-51-926757, 5195
Synonyms:
(-)-(N)-Methyl-N-((1R)-1-methyl-2-phenylethyl)prop-2-yn-1-amine
(-)-Deprenil
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
(R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine
(R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin
(−)-selegiline
14611-51-9
14611-52-0 (hydrochloride)
2079-54-1 (deprenyl.hydrochloride)
AC1L1BTZ
AC1Q2860
AKOS000281115
Anipryl
Apo-Selegiline
BPBio1_000687
BRD-K86434416-001-02-7
BRD-K86434416-003-03-1
BSPBio_000623
BSPBio_001589
C07245
C13H17N
CHEBI:9086
CHEMBL972
CID26757
Carbex
D03731
DB01037
Deprenyl
Eldepryl
Emsam
Emsam (TN)
Gen-Selegiline
HMS1791P11
HMS1989P11
HMS2089D09
Humex
 
Jumex
L-Deprenalin
L-Deprenyl
LS-30156
MolPort-000-883-771
N-methyl-N-[(1R)-1-methyl-2-phenylethyl]prop-2-yn-1-amine
N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine
NCGC00024994-01
NCGC00024994-02
NCGC00024994-03
NCGC00024994-04
Novo-Selegiline
Nu-Selegiline
Prestwick0_000552
Prestwick1_000552
Prestwick2_000552
Prestwick3_000552
SPBio_002544
STK640578
Sd Deprenyl
Selegeline Hcl
Selegilina
Selegilina [INN-Spanish]
Selegiline (USAN/INN)
Selegiline Transdermal System (STS) patch
Selegiline [INN:BAN]
Selegiline, (R)-Isomer
Selegilinum
Selegilinum [INN-Latin]
Selegyline
Tocris-1095
UNII-2K1V7GP655
Yumex
ZINC19632633
Zelapar
l-E 250
selegiline
19
AmantadineapprovedPhase 4, Phase 267768-94-52130
Synonyms:
1-Adamantamine
1-Adamantanamine
1-Adamantanamine (8CI)
1-Adamantylamine
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
1-adamantanamine
1-adamantylamine
1-aminoadamantane
138576_ALDRICH
665-66-7 (hydrochloride)
768-94-5
AB00514655
AC-11992
AC1L1CZI
AC1Q4UAF
AC1Q5396
ADAMANTANE,1-AMINO
AKOS000113994
AKOS000119324
Adamantamine
Adamantanamine
Adamantylamine
Amant
Amantadina
Amantadina [INN-Spanish]
Amantadine
Amantadine (INN)
Amantadine Base
Amantadine HCL
Amantadine Hydrochloride
Amantadine [INN:BAN]
Amantadinum
Amantadinum [INN-Latin]
Amantidine
Ambap768-94-5
Aminoadamantane
BIA4304
BIDD:GT0757
BPBio1_000368
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
Bio-0821
C06818
C10H17N
CHEBI:2618
CHEMBL660
CID2130
D07441
DB00915
DivK1c_000815
EINECS 212-201-2
Endantadine
Gen-Amantadine
HMS1791O12
HMS1989O12
HSDB 3202
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
KBio1_000815
KBio2_000390
 
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
L000868
LS-157049
Lopac-A-1260
Lopac0_000004
Mantadine
MolPort-001-661-700
MolPort-001-760-587
MolPort-001-791-102
NCGC00015036-01
NCGC00015036-07
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
NINDS_000815
NSC 341865
NSC341865
NSC83653
OR14310
Oprea1_248648
Pk-Merz
Pk-merz
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
SPBio_000002
SPBio_002273
STK298781
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
Spectrum_000030
Symadine
Symmetrel
TCMDC-125869
TL8005280
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-ylamine
Tricyclo[3.3.1.1(3,7)]decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
UNII-BF4C9Z1J53
Viregyt
Virosol
WLN: L66 B6 A B- C 1B ITJ BZ
Wiregyt
adamantan-1-amine
adamantan-1-ylamine
amantadine
amantadine hydrochloride
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
20
Tadalafilapproved, investigationalPhase 4149171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
21
Cholineapproved, nutraceuticalPhase 414862-49-7305
Synonyms:
(2-Hydroxyethyl)trimethyl ammonium
(2-Hydroxyethyl)trimethylammonium
(beta-hydroxyethyl)trimethylammonium
2-Hydroxy-N,N,N-trimethyl-ethanaminium
2-Hydroxy-N,N,N-trimethylethanaminium
Bilineurine
Biocolina
Biocoline
Choline
Choline cation
 
Choline ion
Cholinum
Hepacholine
Hormocline
Lipotril
N,N,N-Trimethylethanol-ammonium
N,N,N-Trimethylethanolammonium
N,N,N-trimethylethanol-ammonium
N-trimethylethanolamine
Neocolina
Paresan
trimethylethanolamine
22Dopamine AgentsPhase 4, Phase 3, Phase 2, Phase 13759
23
SerotoninPhase 4, Phase 3, Phase 2, Phase 1356650-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
24Psychotropic DrugsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 16279
25Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 117734
26Dopamine agonistsPhase 4, Phase 3, Phase 2, Phase 1618
27Neurotransmitter Uptake InhibitorsPhase 4, Phase 1, Phase 23464
28N 0437Phase 4, Phase 3, Phase 186
29Cholinergic AgentsPhase 4, Phase 3, Phase 2, Phase 13846
30Adrenergic AgentsPhase 4, Phase 15140
31Neuroprotective AgentsPhase 4, Phase 3, Phase 21672
32Protective AgentsPhase 4, Phase 3, Phase 2, Phase 17190
33Atomoxetine HydrochloridePhase 4168
34Aromatic Amino Acid Decarboxylase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1148
35Nootropic AgentsPhase 4, Phase 3, Phase 2, Phase 1701
36Antidepressive AgentsPhase 4, Phase 1, Phase 2, Early Phase 12666
37Antiparkinson AgentsPhase 4, Phase 3, Phase 2, Phase 11527
38Cholinesterase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1570
39Phosphodiesterase 5 InhibitorsPhase 4, Phase 2571
40Wakefulness-Promoting AgentsPhase 4, Phase 2192
41Cytochrome P-450 CYP3A InducersPhase 4, Phase 21101
42EtiracetamPhase 4, Phase 2200
43Botulinum ToxinsPhase 4669
44Neuromuscular AgentsPhase 41129
45onabotulinumtoxinAPhase 4626
46AnticonvulsantsPhase 4, Phase 2, Phase 12620
47incobotulinumtoxinAPhase 4635
48Botulinum Toxins, Type APhase 4630
49Sildenafil CitratePhase 4, Phase 2323171599-83-0
50Vasodilator AgentsPhase 4, Phase 3, Phase 23438

Interventional clinical trials:

(show top 50)    (show all 414)
idNameStatusNCT IDPhase
1Validation of DaTscan for Detection of Parkinson Disease Related DisordersUnknown statusNCT02138682Phase 4
2The Effect of Donepezil on Gait and Balance in Parkinson's DiseaseUnknown statusNCT01521117Phase 4
3Cognitive Decline in Non-demented PDUnknown statusNCT01340885Phase 4
4Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's DiseaseUnknown statusNCT00354133Phase 4
5Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated PainCompletedNCT01744496Phase 4
6Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And ApathyCompletedNCT01782222Phase 4
7Effect of Intravenous Amantadine on Gait Freezing in Parkinson's DiseaseCompletedNCT01313845Phase 4
8Donepezil to Treat Dementia in Parkinson's DiseaseCompletedNCT00030979Phase 4
9Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic ImpactCompletedNCT00141518Phase 4
10Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's DiseaseCompletedNCT00437125Phase 4
11Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole TreatmentCompletedNCT00651183Phase 4
12Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's DiseaseCompletedNCT00640159Phase 4
13Levodopa Benserazide Generic Formulation Versus the OriginatorCompletedNCT02741947Phase 4
14Virtual Exercises in Patients With Parkinson's Disease.CompletedNCT02023034Phase 4
15The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking ProblemsCompletedNCT00988117Phase 4
16Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's DiseaseCompletedNCT00914134Phase 4
17Mild Cognitive Impairment in Parkinson's DiseaseCompletedNCT01519271Phase 4
18Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) InhibitorsCompletedNCT00906828Phase 4
19Cardiac Valve Complications in Prolactinomas Treated With CabergolineCompletedNCT00460616Phase 4
20Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.CompletedNCT00247247Phase 4
21Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa PharmacokineticsCompletedNCT00888186Phase 4
22Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and TreatmentCompletedNCT00489255Phase 4
23Methylphenidate for the Treatment of Gait Impairment in Parkinson's DiseaseCompletedNCT00526630Phase 4
24A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's DiseaseCompletedNCT01485172Phase 4
25Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive SymptomsCompletedNCT00297778Phase 4
26A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar SymptomsCompletedNCT00382967Phase 4
27An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia FatigueCompletedNCT00678691Phase 4
28Motor Response to Sildenafil in PDCompletedNCT01941732Phase 4
29A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) PatientsCompletedNCT00402233Phase 4
30Amantadine for Improving Neurologic Symptoms in Ataxia-TelangiectasiaCompletedNCT00950196Phase 4
31An Observational Study of BOTOX® as Headache Prophylaxis for Chronic MigraineCompletedNCT01686581Phase 4
32Sagene 2014 - Parkinson's Disease and Erectile DysfunctionRecruitingNCT02225548Phase 4
33Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s DiseaseRecruitingNCT01856738Phase 4
34"Equistasi" and Gait in HemiparesisRecruitingNCT02714478Phase 4
35INfusion VErsus STimulation in Parkinson's DiseaseRecruitingNCT02480803Phase 4
36Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum DisordersRecruitingNCT01098383Phase 4
37Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's DiseaseNot yet recruitingNCT02940912Phase 4
38Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson DiseaseNot yet recruitingNCT03011476Phase 4
39Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).Not yet recruitingNCT02688465Phase 4
40Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's DiseaseTerminatedNCT01519882Phase 4
41Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's DiseaseTerminatedNCT01048229Phase 4
42Keppra IV for the Treatment of Motor Fluctuations in Parkinson's DiseaseWithdrawnNCT00584025Phase 4
43Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's DiseaseWithdrawnNCT00584090Phase 4
44Donepezil Treatment of Psychotic Symptoms in Dementia PatientsUnknown statusNCT00190021Phase 3
45Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With DementiaCompletedNCT01327859Phase 3
46Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)CompletedNCT01227265Phase 3
47Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal PatchCompletedNCT00522379Phase 3
48Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonCompletedNCT01568073Phase 3
49Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's DiseaseCompletedNCT01036139Phase 3
50Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's DiseaseCompletedNCT01066442Phase 3

Search NIH Clinical Center for Parkinson Disease 5

Genetic Tests for Parkinson Disease 5

About this section

Genetic tests related to Parkinson Disease 5:

id Genetic test Affiliating Genes
1 Parkinson Disease 527

Anatomical Context for Parkinson Disease 5

About this section

MalaCards organs/tissues related to Parkinson Disease 5:

36
Brain, Testes, Cortex, Subthalamic nucleus, Prefrontal cortex, Temporal lobe, Lung

Publications for Parkinson Disease 5

About this section

Variations for Parkinson Disease 5

About this section

UniProtKB/Swiss-Prot genetic disease variations for Parkinson Disease 5:

70
id Symbol AA change Variation ID SNP ID
1UCHL1p.Ile93MetVAR_015678rs121917767

Clinvar genetic disease variations for Parkinson Disease 5:

5
id Gene Variation Type Significance SNP ID Assembly Location
1UCHL1NM_004181.4(UCHL1): c.279C> G (p.Ile93Met)SNVrisk factorrs121917767GRCh37Chr 4, 41262768: 41262768

Expression for genes affiliated with Parkinson Disease 5

About this section
Search GEO for disease gene expression data for Parkinson Disease 5.

Pathways for genes affiliated with Parkinson Disease 5

About this section

GO Terms for genes affiliated with Parkinson Disease 5

About this section

Cellular components related to Parkinson Disease 5 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cell bodyGO:00442979.9COMT, MAPT
2dendriteGO:00304259.3COMT, HTR2A, MAPT
3axonGO:00304248.9COMT, HTR2A, MAPT, UCHL1
4cytosolGO:00058298.3COMT, HTR2A, MAPT, SLC6A4, UCHL1
5plasma membraneGO:00058867.5COMT, HTR2A, MAPT, SLC6A4, UCHL1

Biological processes related to Parkinson Disease 5 according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1memoryGO:000761310.0HTR2A, SLC6A4
2adult walking behaviorGO:00076289.9MAPT, UCHL1
3axonogenesisGO:00074099.9MAPT, UCHL1
4female pregnancyGO:00075659.8COMT, MAPT
5response to nutrientGO:00075849.7MAPT, SLC6A4
6response to organic substanceGO:00100339.6MAPT, SLC6A4
7response to drugGO:00424939.4COMT, HTR2A, SLC6A4
8sensory perception of painGO:00192339.4HTR2A, UCHL1

Sources for Parkinson Disease 5

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet